References
- Drew LRH. Controls on clozapine must be reviewed. Aust N Z J Psychiatry 2010; 44:490.
- Schulte PFJ, Cohen D, Bogers JPAM. A Dutch guideline for the use of clozapine. Aust N Z J Psychiatry 2010; 44:1055–1056.
- Lambert TJR, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 18:544–548.
- Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Med J Aust 2009, 190:S39–S42.
- Foley DL, Morley KI, Carroll KE. Successful implementation of cardiometabolic monitoring of patients treated with antipsychotics. Med J Aust 2009; 191:518–519.
- Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. London: Informa Healthcare, 2009:64.
- Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21:579–591.
- Kane J, Honigfeld G, Singer J . The Clozapine Collaborative Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psych 1988; 45:789–796.